FDA Approves Once-Weekly Carfilzomib for Myeloma

FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.

Source: CancerNetwork - October 15, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news